---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002696"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:05.539020+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.
- Company expects the cash position to fund operating expenses and capital expenditures into the first quarter of 2027.
- Amount is preliminary, subject to completion of year-end financial review, adjustments, and audit.

## SEC filing metadata
- accession: 0001104659-26-002696
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/0001104659-26-002696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/tm262847d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002696
- JSON: https://secwatch.observer/filing/0001104659-26-002696.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.